Products are for professional/laboratory use only.
Biocartis is pleased to add a new Idylla EGFR (Epidermal Growth Factor Receptor) Mutation Test to their core oncology menu, that now covers most known and used oncology biomarkers.
Products are for professional/laboratory use only.
Idylla™, Biocartis’ fully automated, real-time PCR based molecular diagnostics system, is designed to offer fast and easy access to clinical molecular diagnostic information, anywhere and anytime.
Products are for professional/laboratory use only.
Molecular diagnostics are rapidly becoming part of the standard of care for cancer patients. This biomarker based approach serves to select patients likely to benefit from targeted treatment regimens and potentially assists in their inclusion into appropriate clinical trials.
Introducing Biocartis Idylla – BRAF molecular results in as little as 90 minutes.
About 50 percent of all melanomas harbor mutations in the BRAF oncogene. Idylla™ BRAF Mutation Test detects BRAF mutations directly from FFPE tissue sections in 90 minutes with less than 2 minutes hands-on time.